BURLINGTON, MA, March 18, 2003—Cognos (NASDAQ: COGN; TSX: CSN), the world leader in business intelligence (BI) and performance management and partner, The Janis Group, today announced that Kos Pharmaceuticals has purchased Cognos' financial analytics and reporting solution and Cognos Metrics Manager. Cognos Metrics Manager enables organizations to actively monitor, analyze, and report at every level of the business and supports balanced scorecarding projects across the enterprise.

"Kos Pharmaceuticals has experienced rapid and substantial growth in the past few years, resulting in the creation of vast amounts of corporate data," said Sharon Leventhal, manager, Midrange Applications at Kos Pharmaceuticals. "By implementing solutions from Cognos and The Janis Group, we are upgrading powerful and flexible reporting and analysis capabilities throughout the company. With Cognos we expect to be able to reduce the time required to input, roll up, and distribute financial reports."

"The Janis Group is focused on delivering solutions that meet the demanding needs of our customers. Through our long-standing partnership with Cognos, JGI has provided a strategic enterprise-wide solution that can now further facilitate Kos' data needs and provide an accelerated return on investment to the enterprise," said Mike Janis, president, The Janis Group.

"The soaring R&D costs in the pharmaceutical industry are mandating that companies find other ways of identifying cost savings and improving business processes," said Bill Stevens, director of life sciences marketing, Cognos. "The breadth and depth of the Cognos solution enables companies to address their specific need, as well as work toward implementing an enterprise solution that will further improve efficiencies and management of corporate performance."

About Kos Pharmaceuticals, Inc:
Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases. The Company's principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, or patient compliance. The Company currently markets Niaspan® and AdvicorT for the treatment of cholesterol disorders. Kos is developing additional products and has proprietary drug delivery technologies in solid-dose and aerosol metered-dose inhalation administration. To learn more about Kos, visit kospharm.com

About the Janis Group:
The Janis Group, Inc. (JGI) is a complete solution provider offering our clients tailored solutions in the areas of E-business, Enterprise Resource Planning (ERP), Human Resource Management Software (HRMS) and Collaborative Commerce. Established in 1982, JGI has successfully implemented over 500 systems. Our focus is to provide end-to-end solutions to Mid-Market and Fortune 500 companies. Our success can be attributed to our guiding principles, our clients, our employees and our partners. Our Principles are: 1) Never lose a good client; 2) Never lose a good employee; 3) Be #1 in all you can do; and 4) Deliver what you promise. JGI can be reached at www.jginfo.com or at 201-712-0505.